Notably, high BCAT1 expression inversely correlates with survival only in AML patients whose cancers were wild-type for TET2 and IDH, consistent with BCAT1 overexpression promoting tumorigenesis via suppression of TET2 function (Raffel et al. 2017). The gene discussed is BCAT1; the disease is cancer.